About Us
Our Focus
EpiHeart is young life science company dedicated to improve long term survival and quality of life of the patients having Cardiac Arterry Bypass Grafting (CABG). Based on intial pre-clinical and clincal results the epicardial transplantation of autologous cells during the CABG surgery reduces the scar tissue and fibrosis causing heart failures
Our Background
EpiHeart is a spin-off company leverageing over 10 years of dedicated research conducted on three continents. Our home is Helsinki, Finland, where we have deep collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University.
Collaboration
Epiheart is open for collaboration. We foresee collaboration possibilites:
- Clinical studies with European and US clinics performing CABG surgeries.
- Distributors able to serve and interact clinics performing CABG surgeries.
- Life Science / Medical Device Investors
Feel free to request further information on our scince, clinical trial program and more.